非对称性二甲基精氨酸与糖尿病脑血管病变

Asymmetric dimethylarginine and diabetes with cerebrovascular diseases

一氧化氮（nitric oxide，NO）足已知最重要的内源性血管舒张因子。内皮型一氧化氮合酶（nitric oxide and enzyme，NOS）的竞争性抑制剂非对称性二甲基精氨酸（asymmetric dimethylarginine，ADMA）可抑制NO的合成，使NO／NOS通路发生障碍，NO合成减少。近年来的研究表明，ADMA与糖尿病脑血管病变的发生和发展有关，为进一步明确该病的发生机制提供了新的见解。

Nitric oxide （NO） is the most important known endogenous vasodilator factor. The competitive inhibitor asymmetric dimethylarginine （ADMA） of endothelial nitric oxide synthase （NOS）inhibits NO synthesis, which makes NO/NOS pathway to be obstructed and the reduction of NO synthesis. The studies in recent years have suggested that ADMA is associated with the occurrence and development of diabetes with cerebrovascular disease. It has provided new insights into further clarifying the mechanism of the disease.